Klindamycin Evolan

Clindamycin, the active ingredient in Klindamycin Evolan, is a lincosamide antibiotic presented as a vaginal formulation for intravaginal use. It is employed to treat bacterial vaginosis in women of reproductive age, targeting anaerobic bacteria that cause the infection.

GNH USA supplies Klindamycin Evolan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality compliance with EU standards and reliable logistics for global distribution. The company adheres to stringent manufacturing practices and provides regulatory documentation to support import and clinical use.

Clindamycin is a lincosamide antibiotic used to treat infections of the vaginal microbiota.

- Bacterial vaginosis: restores normal vaginal flora by eliminating anaerobic bacteria responsible for the condition

Clindamycin may cause a range of adverse reactions, from mild irritation to serious systemic events.

Common Side Effects: - Vaginal irritation or burning sensation - Increased vaginal discharge or itching - Nausea or mild gastrointestinal upset

Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis - Clostridioides difficile‑associated colitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before prescribing Klindamycin Evolan, clinicians should consider several safety measures. - Allergy assessment: confirm no known hypersensitivity to clindamycin or other lincosamides - Indication verification: use only for confirmed bacterial vaginosis - Monitor for C. difficile: watch for persistent diarrhea or colitis symptoms - Hepatic function: exercise caution in patients with liver impairment - Drug interactions: review concomitant medications for potential interactions - Store at below 25°C: keep in the original packaging, protect from moisture and direct light

Clindamycin can interact with several drug classes, affecting efficacy or safety.

Major Interactions (Avoid): - Erythromycin or other macrolides: increased risk of gastrointestinal toxicity - Neuromuscular blocking agents: potentiation of muscle weakness - Warfarin: possible enhancement of anticoagulant effect

Moderate Interactions (Monitor Closely): - Oral contraceptives: reduced hormonal efficacy, advise backup contraception - Azole antifungals (e.g., fluconazole): may increase clindamycin plasma levels - Rifampin: may decrease clindamycin concentrations, reducing therapeutic effect